EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Comparison of FDA and EMA Pregnancy and Lactation Labeling

Dana Kappel iD, Leyla Sahin, Lynne Yao, Shannon Thor, Sandra Kweder iD

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Dana Kappel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of Global Policy and Strategy, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Lactation, Drug Labeling. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust collaboration and dialogue around the need for data and the inclusion of pregnant and lactating individuals in clinical trials. Despite this collaboration, the two agencies have their own standards for the format and content of labeling for these populations. To understand these differences, the pregnancy and lactation labeling sections for 31 approved drugs were compared, and trends were assessed for use of language concordance and discordance related to use during pregnancy and lactation between the 2 agencies. Further analysis evaluated the presence of human data included in the labeling. The EMA and the FDA had high discordance between pregnancy and lactation labeling language, in 68% and 71% of labeling, respectively, and only 10% of pregnancy labeling and 16% of lactation labeling include human data. Concordance in labeling language is not the norm but occurs when there is a sizeable body of human data, animal data suggesting a particular safety issue, drug mechanism of action information, or disease‐specific considerations. This study highlights the need for more human data to inform prescribing decisions in these populations. The results also suggest that there is an opportunity for alignment in labeling across regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LactationDrug LabelingPregnancyFemaleAnimalsUnited StatesHumansUnited States Food and Drug AdministrationBreast FeedingPharmaceutical PreparationsDrug Approval

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Office of Global Policy and Strategy, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Europe Office, Office of Global Policy and Strategy, US Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Dana Kappel, Sandra Kweder

Zitieren

APA

Kappel, D., Sahin, L., Yao, L., Thor, S., & Kweder, S. (2023). A Comparison of FDA and EMA Pregnancy and Lactation Labeling. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2843

Vancouver

Kappel D, Sahin L, Yao L, Thor S, Kweder S. A Comparison of FDA and EMA Pregnancy and Lactation Labeling. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2843

BibTeX
@article{Kappel2023,
  author = {Kappel, Dana and Sahin, Leyla and Yao, Lynne and Thor, Shannon and Kweder, Sandra},
  title = {A Comparison of FDA and EMA Pregnancy and Lactation Labeling},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2843}
}
Kostenlos starten →